Advertisement

Reactions Weekly

, Volume 1761, Issue 1, pp 362–362 | Cite as

Vedolizumab

Prostate adenocarcinoma: case report
Case report
  • 9 Downloads

Reference

  1. Amiot A, et al. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary Pharmacology and Therapeutics 50: 40-53, No. 1, Jul 2019. Available from: URL: http://doi.org/10.1111/apt.15294 - France

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations